Tocilizumab
Brand name: Actemra
Rank #159 of 500 drugs by total cost
$99.5M
Total Cost
24,891
Total Claims
$99.5M
Total Cost
1,188
Prescribers
$3,998
Cost per Claim
235
Beneficiaries
26,222
30-Day Fills
$84K
Avg Cost/Provider
21
Avg Claims/Provider
About Tocilizumab
Tocilizumab (sold as Actemra) was prescribed 24,891 times by 1,188 Medicare Part D providers in 2023, costing the program $99.5M. At $3,998 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 156 | Quetiapine Fumarate (Quetiapine Fumarate) | $100.9M | 3,820,737 |
| 157 | Ubrogepant (Ubrelvy) | $100.6M | 75,781 |
| 158 | Darunavir/Cobicistat (Prezcobix) | $99.7M | 38,374 |
| 159 | Tocilizumab (Actemra) | $99.5M | 24,891 |
| 160 | Omalizumab (Xolair) | $98.9M | 30,451 |
| 161 | Brimonidine Tartrate (Alphagan P) | $98.8M | 988,570 |
| 162 | Dexlansoprazole (Dexlansoprazole Dr) | $98.7M | 275,116 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology